

## Inotropic and chronotropic effects of 1-hydroxy-2-methylquinolin-3(1H)-one derivatives in isolated rat atria

Mansouri, S.M.-T.<sup>a</sup>, Shafiee-Nick, R.<sup>b</sup>, Parsaee, H.<sup>b</sup>, Seyedi, S.M.<sup>c</sup>, Saberi, M.-R.<sup>d</sup>, Sadeghian, H.<sup>c</sup>

<sup>a</sup> Dept. of Pharmacology, School of Medicine, Ahvaz Jondishapour University of Medical Sciences, Ahvaz, Iran

<sup>b</sup> Dept. of Pharmacology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>c</sup> Dept. of Organic Chemistry, School of Sciences, Ferdowsi University, Mashhad, Iran

<sup>d</sup> Dept. of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

[View references \(7\)](#)

### Abstract

**Background:** Selective phosphodiesterase (PDE<sup>3</sup>) inhibitors improve cardiac contractility and may use in congestive heart failure. However, their proarrhythmic potential is the most important side effect. **Methods:** In this research, we evaluated the potential cardiotoxic activity of six new synthesized selective PDE<sup>3</sup> inhibitors (1-hydroxy-2-methylquinolin-3(1H)-one derivatives) using the spontaneously beating atria model. In each experiment, atrium of reserpine-treated rat was isolated and the contractile and chronotropic effects of a synthesized compound were assessed. The 3-isobutyl-1-methylxanthine, a non-selective PDE inhibitor, was used for comparison. **Results:** The results showed that, among new compounds, the best pharmacological profile was obtained with the compound 1-[(2-methylpiperazine-1-yl)-2-oxobutoxy]-2-methylquinolin-3(1H)-one, C<sup>1</sup>, which displayed selectivity for increasing the force of contraction (128 ± 8% change over the control) rather than the frequency rate (138 ± 8% change over the control) at 300 μM. However, C<sup>1</sup> at concentrations of 10 and 100 μM produced left and upward shift in the positive inotropic concentration-response curve of isoprenaline. The -log EC<sub>50</sub> of isoprenaline was 8.84 ± 0.17 in the absence, 9.44 ± 0.13 and 9.56 ± 0.17 in the presence of 10, 100 μM of C<sup>1</sup>, respectively (P < 0.001, n = 6). Also, amrinone, a selective PDE<sup>3</sup> inhibitor, shifted the isoprenaline concentration-response curve to the left and upward. The concentration of 10 and 100 μM amrinone decreased -log EC<sub>50</sub> of isoprenaline to 9.27 ± 0.28 and 9.43 ± 0.23, respectively (P < 0.001, n = 6). Moreover, the positive chronotropic effect of isoprenaline was not affected by amrinone or C<sup>1</sup>. **Conclusion:** This study provides functional evidence for the positive inotropic effect of C<sup>1</sup>. Considering the augmentation of isoprenaline positive inotropic concentration-response with C<sup>1</sup> and amrinone, we conclude that C<sup>1</sup> produces its effect via potentiation of cAMP-dependent signaling system and possibly by inhibition of PDE<sup>3</sup> activity.

### Reaxys Database Information

### Author keywords

2-methylquinolinone derivatives; Inotropic activity; Isoprenaline; Phosphodiesterase inhibitor; Rat atria

### Indexed Keywords

**EMTREE drug terms:** 1,2-dihydro 2-methyl-2-oxoquinolin-3(1H)-one cyclohexyl n-methylbutanamide; 1,2-dihydro 2-methyl-2-oxoquinolin-3(1H)-one n-methyl n-phenylbutanamide; 1-[(2-methylpiperazine-1-yl)-2-oxobutoxy]-2-methylquinolin-3(1H)-one; 1-hydroxy-2-methylquinolin-3(1H)-one; 1-hydroxyquinolin-3(1H)-one; amrinone; cyclic AMP; ethyl 1,2-dihydro 2-methyl-2-oxoquinolin-3(1H)-onebutanoate; isobutylmethylxanthine; isoprenaline; phosphodiesterase III inhibitor; phosphodiesterase inhibitor; reserpine

**EMTREE medical terms:** animal tissue; article; chronotropism; concentration (parameters); controlled study; drug activity; drug effect; drug selectivity; enzyme inhibition; heart atrium; heart muscle contractile force; heart muscle contractility; heart rate; inotropism; male; nonhuman; rat

**MeSH:** Amrinone; Animals; Atrial Function; Cardiotoxic Agents; Cyclic Nucleotide Phosphodiesterases, Type 3; Dose-Response Relationship; Drug; Heart Rate; Isoproterenol; Male; Phosphodiesterase Inhibitors; Quinolines; Rats;